2023 Volume 143 Issue 9 Pages 701-706
The nuclear receptor superfamily comprises 48 members in humans. In various organs, nuclear receptors regulate a variety of physiological functions through transcription of target genes. They are associated with the development and progression of endocrine and metabolic disorders, as well as with cancer development. Therefore, agonists and antagonists targeting nuclear receptors are currently being developed as therapeutic drugs for these diseases. Nuclear receptors can be activated through ligand binding or phosphorylation, which is mediated by various cellular signaling pathways. Activation of a nuclear receptor necessitates significant structural modifications in each of its domains. My research has been focused on unraveling the intricate mechanisms underlying the activation of nuclear receptors using constitutive androstane receptor (CAR) and pregnane X receptor (PXR) as model nuclear receptor proteins. CAR and PXR are highly expressed in the liver and are activated by a wide range of xenobiotics. Given their crucial roles in the metabolism and disposition of xenobiotics, as well as their potential in mediating drug–drug interactions, it is imperative to extensively study the mechanisms of xenobiotic-induced activation of these receptors. Such studies are essential for advancements in drug development, as well as for ensuring food and chemical safety. In this review, I elucidate the molecular basis underlying the activation of xenobiotic-responsive nuclear receptors.
